

Enduring Learner Notification

Mid-Atlantic Section of the American Urological Association
2024 Advanced Practice Provider Day
October 20, 2024 – October 20, 2025 - Online

Acknowledgement of Financial Commercial Support

Accord BioPharma

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Mid-Atlantic Section of the American Urological Association (MAAUA). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation #4008163.

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this **enduring material** for a maximum of **4.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives - After Attending This Program You Should Be Able To

1. Discuss management of the transgender patient in Urology and how to manage hospital consults.
2. Discuss cutting edge management strategies for prostate cancer, noninvasive bladder cancer, and renal cancer.
3. Identify appropriate referral for pelvic floor dysfunction patients.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
MARIA	ANOSOVA-SMITH	NA
Jan	Buhler	NA
Adele	Caruso	NA
Lisa	Chuong	NA
Kara	Cossis	Astellas:Speakers Bureau,Myriad:Speakers Bureau,Janseen :Speakers Bureau,Bayer:Speakers Bureau,POCN:Consultant,Theralogix:Private Stock Shareholder,AstraZenica:Consultant
Kara	Cossis	NA
Abigail	Davenport	NA
Justin	Friedlander	BD:Consultant
Eric	Ghiraldi	NA
Kristy	Keyock	NA
Kevin	Kline	NA
Judy	Linh	NA
Keith	Regets	Halozyme:Speakers Bureau,Endo Pharmaceuticals:Consultant,Boston Scientific:Consultant
Tracy	Sandstrom	NA
Terran	Sims	coloplast usa:Consultant